EU/EEA antitrust trackers

This table summarises and tracks all completed investigations carried out by the national competition authorities (NCAs) of all EU/EEA Member States into alleged cartels, anti-competitive agreements and abuses of dominant positions (Articles 101/102 TFEU and national equivalents). A tracker detailing all competition law dawn raids in the EU and EEA is also included.

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

TAKE A FREE TRIAL

Latest Competition News

UK Competition law—daily round-up (21/11/2024)

A round-up of UK competition law developments, including (amongst other things) the CMA’s response to the Government's Industrial Strategy Green Paper and publishes speech by Sarah Cardell on how the CMA ‘is rising to the challenge on growth’.

EU Competition law—daily round-up (21/11/2024)

A round-up of EU competition law developments, including (amongst other things) the latest EUMR and State aid developments.

Competition weekly highlights—21 November 2024

This week's edition of Competition weekly highlights includes, from a UK perspective: (1) the CMA refers to phase 2 with the following mergers: Boparan/ForFarmers (Burston and Radstock mills) and GXO/Wincanton, (2) the CAT’s judgment setting aside CMA’s remittal in Pfizer/Flynn phenytoin sodium capsules investigation, remaking the decision and imposing fines largely matching those previously issued by the CMA, and (3) the CMA’s decision to launch a consultation on draft new guidance for road fuel monitoring. This week's highlights also includes, from an EU perspective: (1) the Commission’s decision to fine Meta €797m for Facebook Marketplace abuses, and (2) the Commission’s announcement that Booking.com must comply with all relevant obligations under the Digital Markets Act.

UK Competition law—daily round-up (20/11/2024)

A round-up of UK competition law developments, including (amongst other things) (1) the CMA’s announcement that it has referred to phase 2 the Boparan/ForFarmers (Burston and Radstock mills) merger, and (2) the CAT’s judgment setting aside CMA’s remittal in Pfizer/Flynn phenytoin sodium capsules investigation, remaking the decision and imposing fines largely matching those previously issued by the CMA.